Ethylene Oxide EtO for Law Firms 2026: Case Volume, Economics and Advertising Strategy

Why Ethylene Oxide Is on Every Smart Plaintiff Firm's Radar Right Now

Ethylene oxide mass tort marketing has become one of the highest-priority case acquisition conversations inside plaintiff firms, driven by a claimant pool spanning hundreds of thousands of residents living near active and legacy sterilization facilities nationwide. The 2022 Sterigenics Willowbrook verdict of $363 million and the subsequent $408 million settlement established plaintiff-favorable precedent that now supports litigation targeting Medline, Becton Dickinson, STERIS, and other operators. For firms evaluating entry timing and budget allocation, the litigation is expanding, not contracting.

The question is not whether EtO litigation has legs. It clearly does. The question is whether your firm is positioned to capture cases in the active exposure geographies before acquisition costs climb and the addressable pool shrinks. Let's walk through the economics, the litigation timeline, and what running a real EtO campaign actually looks like.

The Litigation Landscape: What MDL Status and Verdicts Mean for Your Investment Timing

EtO cases are coordinated in the Northern District of Illinois but have not been consolidated into a formal MDL. That distinction matters for firms evaluating how long before cases resolve and capital comes back. The absence of a single MDL judge running a strict bellwether schedule means timelines are less predictable than in a traditional MDL, but it also means the litigation is still early enough in many jurisdictions that firms can sign cases with realistic value expectations.

The Sterigenics Willowbrook chapter is largely closed. That $408 million settlement covered the Willowbrook, Illinois community, and per-case benchmarks from that settlement are now part of how defense and plaintiff counsel think about value across the broader EtO docket. A $363 million first verdict for a single plaintiff is an extraordinary data point. It signals that juries take this causation theory seriously, that proximity-based exposure claims can survive Daubert, and that defendants face genuine financial exposure.

The active litigation now centers on Medline Industries in Waukegan, Becton Dickinson in Covington, Georgia, and STERIS in Laredo, Texas. These cases are moving, trials are ongoing, and the filing trend continues to grow. For firms thinking about when to spend on acquisition, this is a middle-inning tort. Willowbrook proved the theory. The next wave of facility-specific litigation is where firms can still build meaningful inventories without competing in a fully saturated market.

One practical note: cases that go to trial create news. Local news coverage of EtO trials in Illinois and Georgia has a real effect on inbound lead volume from those geographies. Firms running paid campaigns should be watching trial calendars and prepared to scale spend during high-visibility moments.

The Claimant Pool: Volume, Geography, and Saturation

Active plaintiff counts across EtO sterilization facility cases sit above 2,000, but that number understates the total addressable population. Studies of residential exposure zones around operating EtO facilities consistently identify communities of tens of thousands of people living within one to three miles of these sites. Many of those residents have never been contacted by a plaintiff firm. Awareness of EtO as a health hazard remains low outside of Willowbrook, where litigation drove saturation through years of local media coverage.

Geographic concentration is both the tort's greatest asset and its primary constraint. This is not a national mass tort where you can run broad demographic targeting and find claimants in every state. EtO acquisition requires precision. The high-value exposure zones are Waukegan, Illinois; Covington, Georgia; Laredo, Texas; and Atlanta-area BD facilities. Firms that invest in hyper-local targeting around these zip codes and census tracts will outperform firms running unfocused national buys.

Saturation in Willowbrook is real. That community has been heavily worked by plaintiff firms for years. Waukegan, Covington, and Laredo are meaningfully less saturated. Cost-per-lead in those markets is still at a level where acquisition economics make sense. That window will close as more firms enter those geographies, so firms evaluating this tort should be thinking about Q3 and Q4 acquisition windows, not a future date.

Ethylene Oxide Mass tort Marketing: The Acquisition Economics

Ethylene oxide mass tort marketing works differently than a national tort like Camp Lejeune or AFFF. The addressable population is geographically constrained, which compresses both cost and volume. Here is what firms should realistically expect.

Cost-per-lead in active EtO exposure geographies is running roughly $150 to $350 depending on the platform, the creative, and how competitive a given zip code is. That range is favorable compared to many mass torts. The tighter geography means spend can be concentrated efficiently rather than spread thin across national campaigns that generate leads requiring complex qualification screening.

Cost-per-signed case is more variable and depends heavily on intake speed and qualification depth. Firms with strong, fast intake operations are converting EtO leads at retainer costs in the $1,500 to $3,500 range. Firms with slow follow-up or weak intake scripts are paying significantly more, not because leads are bad but because contact rates and conversion rates drop sharply when leads age past 24 to 48 hours.

On the channel side, Facebook and Instagram remain the highest-volume platforms for EtO acquisition in residential exposure communities. Local awareness is the key creative angle. Campaigns that reference the specific facility name, the city, and the documented EPA findings outperform generic cancer-focused creative. The Kamuda verdict and the $408 million settlement are credibility signals that convert in this tort. People in these communities have often heard of the litigation even if they have not connected it to their own health history.

Programmatic display and geofenced digital can supplement paid social with proximity-based targeting around specific facility addresses. YouTube pre-roll with locally-contextualized creative performs in markets like Waukegan where there is existing community awareness.

Intake and Qualification: How Firms Should Screen and Retain EtO Cases

The qualification logic for EtO cases is straightforward but requires discipline in execution. Two conditions must be met: documented proximity (typically one to three miles from a confirmed EtO facility for at least one year) and a qualifying diagnosis, primarily breast cancer and non-Hodgkin lymphoma, though other EtO-linked cancers are supported in the literature.

The proximity question is where most intake operations create friction. Intake staff need to be trained to capture the claimant's residential address and work history during the first call, not later in a follow-up. The residential proximity analysis, mapping the address against the documented exposure plume for the relevant facility, should happen before a retainer is signed. Firms that skip this step sign cases that do not survive expert review, which wastes money and time.

The diagnosis piece requires medical record confirmation. Intake should collect authorization for records early in the process and have a system to follow up on record retrieval within a defined window. Cases without confirmed diagnosis and confirmed proximity are contingent liabilities on your docket, not assets.

Retainer flow should be digital and fast. EtO claimants skew older, which means intake operations should account for phone-first communication and offer DocuSign or similar electronic signature options that work on a phone without friction. Cases that require a claimant to print, sign, and mail documents will lose conversion rate.

How MTAA Approaches EtO Campaigns

At Mass Tort Ad Agency, we have managed over $250 million in Facebook ad spend across more than 100 mass torts for over 600 plaintiff firms. EtO is a tort where geographic precision separates profitable campaigns from expensive ones, and precision is where we spend our time.

We run on a transparent cost-plus model. Firms pay actual ad spend plus a 15% management fee. No hidden markups on media. When we build an EtO campaign, we are targeting specific zip codes and census tracts in the documented exposure zones, building creative that references the local facility context, and optimizing toward signed cases rather than raw lead volume. We handle full campaign management so firm staff are not spending time on ad platform logistics.

For firms considering EtO acquisition, the conversation starts with geography. Which facilities are in scope, what is your intake capacity, and what is your target signed-case cost? Those three inputs shape the entire campaign structure. AI tools are increasingly useful for accelerating intake documentation, summarizing medical records, and drafting proximity analysis workflows inside firms. For firms that want to think about where AI fits into their broader case acquisition and management operations, our book "A Lawyer's Guide to AI" covers practical applications across exactly these kinds of workflows.

The Window Is Open, But It Will Not Stay That Way

Ethylene oxide mass tort marketing is in a phase where firms that move thoughtfully and with geographic discipline can still build meaningful case inventories at reasonable acquisition costs. The Willowbrook verdict and settlement established both the legal theory and the value benchmarks. The Waukegan, Covington, and Laredo dockets are active and growing. Saturation in those markets is real but not yet prohibitive.

Firms that wait for a fully mature MDL schedule, national media saturation, and textbook bellwether timelines will find that acquisition costs have doubled and the best cases have already been signed. Ethylene oxide mass tort marketing rewards early, disciplined entry in targeted geographies, not broad national campaigns and not last-minute inventory building after trials produce headlines. The firms winning this tort are the ones building docket position now, with campaigns structured around real exposure data and intake operations tight enough to convert at scale.